Wentian Huang, MD
Internal Medicine · Garland, TXNPI 1700863560
Payments from drug & device makers
Across 182 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$976
- Bayer$287
- Amgen$283
- Boehringer Ingelheim$269
- Novo Nordisk$265
- Merck$262
- plus $849 from 20 others
What the payments were for
- Food & beverage$3,185100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $976 |
| Bayer | 15 | $287 |
| Amgen(2 entities) | 15 | $283 |
| Boehringer Ingelheim | 13 | $269 |
| Novo Nordisk | 19 | $265 |
| Merck | 13 | $262 |
| Gilead | 6 | $124 |
| Pfizer | 5 | $100 |
| GSK | 5 | $89 |
| Exact Sciences | 4 | $80 |
| Hologic Sales And Service, LLC | 2 | $72 |
| Amarin Pharma, Inc. | 3 | $60 |
| Arbor Pharmaceuticals, Inc. | 3 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $26 |
| Optinose US, Inc. | 2 | $26 |
| Abbott | 1 | $25 |
| Si-bone, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Linus Health, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPVAXIVE$102
How this compares
$3,191 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 177 | $226,038 |
| JanuviaSitagliptin Phosphate | 160 | $217,373 |
| JardianceEmpagliflozin | 105 | $140,782 |
| VascepaIcosapent Ethyl | 179 | $133,923 |
| ProliaDenosumab | 73 | $123,926 |
| JanumetSitagliptin Phos/Metformin Hcl | 73 | $102,731 |
| OzempicSemaglutide | 82 | $102,267 |
| TradjentaLinagliptin | 86 | $101,287 |
| MounjaroTirzepatide | 36 | $53,127 |
| TrulicityDulaglutide | 24 | $52,574 |
| Omega-3 Acid Ethyl Esters | 166 | $27,936 |
| VemlidyTenofovir Alafenamide | 15 | $24,485 |
| LivaloPitavastatin Calcium | 28 | $20,579 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $18,478 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $17,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $262 | $335,213248 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $976 | $251,750215 claims |
| Boehringer IngelheimJardiance, Tradjenta | $269 | $242,068191 claims |
| AmgenProlia | $283 | $123,92673 claims |
| Lilly USA, LLCMounjaro, Trulicity | $26 | $105,70160 claims |
| Novo NordiskOzempic | $265 | $102,26782 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $89 | $26,15036 claims |
| GileadVemlidy | $124 | $24,48515 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $31 | $20,57928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Garland
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.